Alcon to acquire Eysuvis drops for the treatment of dry eye disease

[ad_1]

GENEVA — Alcon has signed an agreement to acquire Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals Inc.

The acquisition of eye drops (0.25% loteprednol etabonate suspension) “will complement Alcon’s existing portfolio in the fast-growing dry eye category,” according to a press release.

Alcon will pay $60 million in upfront consideration to Kala. Alcon “may be required to make additional contingent payments upon achieving certain business milestones,” according to the statement.

The transaction is expected to close in the third quarter.

More version:

EYSUVIS will complement the Systane eye drop family, which includes the recently launched preservative-free Systane formulations, now available in a convenient multi-dose bottle. While the Systane family is used for the ongoing management of dry eye symptoms, EYSUVIS will provide eye care professionals (ECPs) with a short-term treatment option to alleviate dry eye disease.

More than 30 million people in the United States suffer from dry eye. Alcon research shows that approximately 20-25% of dry eye patients experience acute episodes of dry eye on average twice a year. EYSUVIS, a corticosteroid, can be prescribed by ECPs during these episodes of acute dry eye.

EYSUVIS was approved by the U.S. Food & Drug Administration in January 2021 as the first and only corticosteroid indicated for up to two weeks of treatment for the signs and symptoms of dry eye disease. The prescription treatment uses a proprietary drug delivery technology known as AMPPLIFY to enhance penetration of loteprednol etabonate into targeted tissues on the ocular surface, helping to prevent flare-ups associated with dry eye disease .

“We will be delighted to add EYSUVIS to our growing pharmaceutical portfolio,” said Sergio Duplan, President, North America at Alcon. “EYSUVIS is a natural choice for our new eye drop sales force in the United States. With our strong expertise in market access and commercial execution, we are well positioned to grow the acute dry eye treatment market.

As part of the agreement, Alcon will also acquire INVELTYS (loteprednol etabonate suspension) 1%the only corticosteroid for the twice-daily treatment of postoperative inflammation and pain following eye surgery.

Advertising

[ad_2]
Source link

Comments are closed.